Denali Therapeutics Inc. (DNLI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases using its TransportVehicle (TV) platform. The company has no approved products and has not generated product revenue to date.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Loss | $(124.1) million | $(99.0) million | $(257.1) million | $(200.8) million |
| Net Loss Per Share | $(0.72) | $(0.59) | $(1.50) | $(1.26) |
| Research & Development Expenses | $102.7 million | $91.4 million | $218.9 million | $198.4 million |
| General & Administrative Expenses | $32.3 million | $25.2 million | $61.6 million | $50.4 million |
| Interest & Other Income, Net | $10.8 million | $17.6 million | $23.5 million | $33.5 million |
| Cash, Cash Equivalents & Marketable Securities | $977.4 million (as of June 30, 2025) | |||
| Accumulated Deficit | $1.80 billion (as of June 30, 2025) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 16% in Q2 2025 compared to Q2 2024. R&D expenses increased by $11.3 million, driven by higher external spend on TransportVehicle (TV) programs and increased personnel costs related to the commencement of operations at the Salt Lake City manufacturing facility.
- Decreased Small Molecule Spend: External R&D expenses for small molecule programs decreased by $9.8 million in Q2 2025, primarily due to the winding down of the Phase 2/3 HEALEY ALS Platform Trial for DNL343.
- Lower Interest Income: Interest and other income decreased by 38% in Q2 2025 compared to the prior year, reflecting changes in the investment portfolio and interest rates.
- Collaboration Terminations: The company terminated collaboration programs with Sanofi (CNS Products) and Takeda (ATV:TREM2) in early 2025, eliminating future milestone and royalty potential for these specific assets.
Guidance, Outlook, and Management Commentary
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($977.4 million) are sufficient to fund operations for at least the next 12 months.
- Regulatory Milestones:
- DNL310 (Hunter Syndrome): The FDA accepted the Biologics License Application (BLA) for priority review with a PDUFA target action date of January 5, 2026.
- DNL126 (Sanfilippo Syndrome): The FDA agreed that cerebrospinal fluid heparan sulfate (CSF HS) may serve as a surrogate endpoint for accelerated approval. Planning for a confirmatory Phase 3 study is underway.
- Manufacturing: The clinical biomanufacturing facility in Salt Lake City officially opened in March 2025, expanding U.S. capabilities.
- Risks: The company faces significant risks related to clinical trial outcomes, regulatory approvals, and the need for additional capital in the long term. Stock price volatility and potential dilution from future financing are noted risks.
Key Facts for Investor Verification
- Capital Runway: Verify the sufficiency of the $977.4 million cash position against projected burn rates, especially given the $1.80 billion accumulated deficit.
- DNL310 Approval Timeline: Monitor the FDA's decision on the BLA for DNL310, expected by January 5, 2026, as this is the primary near-term catalyst for revenue.
- Manufacturing Costs: Assess the impact of the new Salt Lake City facility on operating expenses, which contributed to the increase in R&D and G&A costs.
- Collaboration Revenue: Confirm the status of remaining collaboration agreements (Biogen, Takeda PTV:PGRN) and the recognition of deferred R&D funding liabilities ($30.3 million total).
- Pre-Funded Warrants: Note the existence of 26.0 million pre-funded warrants outstanding, which are immediately exercisable at $0.01 per share, representing potential dilution.